Loading...
XSHE002198
Market cap471mUSD
Jan 09, Last price  
6.81CNY
1D
-0.29%
1Q
10.19%
Jan 2017
-49.47%
IPO
88.82%
Name

Guangdong Jiaying Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002198 chart
P/E
100.70
P/S
6.48
EPS
0.07
Div Yield, %
0.00%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
-0.14%
Revenues
533m
-19.11%
37,459,98654,347,67362,670,41964,580,60666,345,31462,332,07075,247,15785,913,205104,473,155226,744,884565,820,205475,805,044449,950,868468,080,735536,983,626500,504,004544,728,979574,713,387659,195,732533,233,202
Net income
34m
-21.88%
2,769,23115,418,55222,113,00324,419,26813,721,12915,078,69525,246,95720,238,5827,568,064139,490,54873,653,92766,354,92155,172,042035,878,607019,838,3481,477,26943,934,70334,320,234
CFO
98m
+262.57%
8,784,73217,631,06326,367,49618,348,68610,712,98527,980,48619,695,231781,8955,271,56919,461,599103,362,81342,312,92153,126,86930,631,91762,102,73712,963,92196,873,55051,800,13227,154,40198,453,750
Dividend
Jun 21, 20240.05 CNY/sh
Earnings
May 23, 2025

Profile

Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in Mainland China, Taiwan, Hong Kong and Macao, Southeast Asia, Europe, the United States, and internationally. The company provides medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, and gastrointestinal diseases. It offers products in various dosage forms, such as powders, tablets, capsules, granules, and pills. The company sells its products through distribution agencies and sales outlets. Guangdong Jiaying Pharmaceutical Co., Ltd. is based in Meizhou, China.
URL
http://www.gdjyzy.com.cn/
IPO date
Dec 18, 2007
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
533,233
-19.11%
659,196
14.70%
Cost of revenue
488,436
563,761
Unusual Expense (Income)
NOPBT
44,797
95,435
NOPBT Margin
8.40%
14.48%
Operating Taxes
5,053
7,163
Tax Rate
11.28%
7.51%
NOPAT
39,743
88,272
Net income
34,320
-21.88%
43,935
2,874.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,774
Long-term debt
Deferred revenue
413
539
Other long-term liabilities
1
Net debt
(361,131)
(228,345)
Cash flow
Cash from operating activities
98,454
27,154
CAPEX
(5,061)
Cash from investing activities
(150,239)
Cash from financing activities
(445)
FCF
94,926
56,100
Balance
Cash
334,037
234,119
Long term investments
27,094
Excess cash
334,469
201,159
Stockholders' equity
666,555
605,011
Invested Capital
428,929
516,360
ROIC
8.41%
18.03%
ROCE
5.61%
12.69%
EV
Common stock shares outstanding
507,696
507,510
Price
7.28
11.66%
6.52
-17.26%
Market cap
3,696,025
11.70%
3,308,964
-17.26%
EV
3,362,117
3,080,619
EBITDA
69,009
121,327
EV/EBITDA
48.72
25.39
Interest
454
Interest/NOPBT
0.48%